Efficacy and Safety of Aidi Injection Combined with Transcatheter Arterial Chemoembolization on Primary Hepatic Carcinoma: A Systematic Review and Meta-Analysis.

Weihao Chen,Xudong Chen,Ya Xiao,Yurong Wang,Ruixue Chen,Liguo Chen,Yun Zhang,Qiuer Liang,Yunfei Cai

doi:10.1155/2018/6376429

Weihao Chen, Xudong Chen + Show 7 more

Open Access

https://doi.org/10.1155/2018/6376429

Copy DOI

Abstract

Objectives To evaluate the efficacy and safety of Aidi injection (ADI) combined with transcatheter arterial chemoembolization (TACE) for primary hepatic carcinoma (PHCC). Methods We conducted a literature search in EMBASE, PubMed, CENTRAL, MEDLINE, CNKI, Wanfang, and VIP databases from the earliest possible year to April 2018. Randomized controlled trials (RCTs) involving ADI combined with TACE versus TACE alone for patients with PHCC were included. The Cochrane Risk of Bias tool was applied for quality assessment. Results 22 studies involving 1611 participants were included. The clinical response rate (RR = 1.28, 95% CI: 1.17-1.40; P < 0.00001), KPS score (RR = 1.78, 95% CI: 1.59-2.00; P < 0.00001), survival rate (RR = 1.27, 95% CI: 1.16-1.39; P < 0.00001), immune function (MD = 1.24, 95% CI: 0.98-1.51; P < 0.00001), and adverse effects (RR = 0.62, 95% CI: 0.57-0.68; P < 0.00001) of ADI plus TACE showed significant difference when compared with TACE alone. ConclusionsADI combined with TACE in the treatment of PHCC improved the clinical response rate and safety compared to TACE alone. However, due to poor methodological quality of many of the included RCTs, more rigorously designed and large-scale RCTs are warranted to examine this beneficial effect in the future.

Highlights

Primary hepatic carcinoma (PHCC) is the 5th most common malignant tumor of digestive system in the world, which accounts for 90% of its pathological type
The results showed that Aidi injection (ADI) combined with transcatheter arterial chemoembolization (TACE) significantly improved the clinical response rate of patients with PHCC when compared with TACE alone (RR = 1.28, 95% confidence intervals (CI): 1.171.40; P < 0.00001) (Figure 2)
The results showed that there was no statistical difference between two groups and ADI combined with TACE group did not affect the expression level of CD4+/CD8+ (MD = 0.18, 95% CI: -0.10-0.45; P = 0.2) (Figure 5)

Summary

Introduction

Primary hepatic carcinoma (PHCC) is the 5th most common malignant tumor of digestive system in the world, which accounts for 90% of its pathological type. More than 500,000 people in the world suffered from PHCC every year, and 55% of them are in China [3, 4]. The methods in the treatment of PHCC were surgery, hepatic artery ligation, liver transplantation, transcatheter arterial chemoembolization (TACE), radiofrequency ablation, cryotherapy, laser, and biological therapy. 70%-80% patients with PHCC have been diagnosed as advance or distant metastasis when they visited the doctor [5]. Many patients of PHCC had severe complication of cirrhosis which results in an inability to undergo the surgical treatment and poor prognosis

Objectives

Results

Discussion

Conclusion